David A. Cooper

Simplification of Antiretroviral Therapy with Tenofovir‐Emtricitabine or Abacavir‐Lamivudine: A Randomized, 96‐Week Trial

Allison Martin, Mark Bloch, Janaki Amin et al. · Clinical Infectious Diseases · 2009 · 222 citations · Full text

Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

Roy T. Steigbigel, David A. Cooper, Hedy Teppler et al. · Clinical Infectious Diseases · 2010 · 204 citations · Full text

Immunology, Pharmacotherapy, Antiviral Drug +16

Dual Efficacy of Lamivudine Treatment in Human Immunodeficiency Virus/Hepatitis B Virus–Coinfected Persons in a Randomized, Controlled Study (CAESAR)

Gregory J. Dore, David A. Cooper, Catherine Barrett et al. · The Journal of Infectious Diseases · 1999 · 145 citations · Full text

Mediators of Innate and Adaptive Immune Responses Differentially Affect Immune Restoration Disease Associated with<i>Mycobacterium tuberculosis</i>in HIV Patients Beginning Antiretroviral Therapy

Benjamin G. Oliver, Julian Elliott, Patricia Price et al. · The Journal of Infectious Diseases · 2010 · 77 citations · Full text

Polyclonal Proliferation and Apoptosis of CCR5⁺T Lymphocytes during Primary Human Immunodeficiency Virus Type 1 Infection: Regulation by Interleukin (IL)–2, IL‐15, and Bcl‐2

John Zaunders, Laure Moutouh–de Parseval, Shinichi Kitada et al. · The Journal of Infectious Diseases · 2003 · 66 citations · Full text